Physician profile
Stanislav Ilyusha
NPI 1750334264
$3,347.85
in general payments reported to CMS, 2019-2025
15 companies · $927 in 2025
The $927 reported for 2025 was more than what 83% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $148 · 2021: $330 · 2022: $325 · 2023: $357 · 2024: $510 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $560.78 | 2021-2025 | Tryptyr, Total30 |
| Bausch & Lomb Americas INC. | $479.60 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $350.68 | 2019-2023 | Acuvue |
| Glaukos Corporation | $274.88 | 2024 | Ce-Marked Kxla System |
| Allergan, INC. | $253.79 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $249.73 | 2019 | |
| Amgen INC. | $239.70 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $186.39 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $149.71 | 2021 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $124.99 | 2019 | |
| Dompe US, INC. | $120.44 | 2025 | Oxervate |
| Abbvie INC. | $116.69 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $96.07 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislav Ilyusha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.